Genetic abnormalities of somatostatin receptors in pituitary tumors

Molecular and Cellular Endocrinology

Volumn 286, Issue 1-2, 2008, Pages 180-186

  Lania, A ^a   Mantovani, G ^a   Spada, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acromegaly; LOH; Pituitary adenoma; Somatostatin; Somatostatin receptors; TSH oma

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; AMINO ACID SUBSTITUTION; ARTICLE; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG BINDING; DRUG EFFECT; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPOPHYSIS TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 43549096868     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.08.013     Document Type: Article

References (69)

1. L.F. Allen R.J. Lefkowitz M.G. Caron S. Cotecchia G-protein coupled receptor genes as protooncogenes: constitutively activating mutation of the α1B-adrenergic receptor enhances mitogenesis and tumorigenicity Proc. Natl. Acad. Sci. U.S.A. 88 1991 11354 11358
2. B.A. Amendt L.B. Sutherland A.F. Russo Transcriptional antagonism between Hmx1 and Nkx2.5 for a shared DNA-binding site J. Biol. Chem. 274 1999 11635 11642
3. S.L. Asa S. Ezzat The pathogenesis of pituitary tumors Nat. Rev. 2 2002 836 849
4. C. Asteria M. Anagni L. Persani P. Beck-Peccoz Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas J. Endocrinol. Invest. 24 2001 796 801
5. E. Ballarè L. Persani A.G. Lania M. Filopanti E. Giammona S. Corbetta S. Mantovani M. Arosio P. Beck-Peccoz G. Faglia A. Spada Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment J. Clin. Endocrinol. Metab. 86 2001 3809 3814
6. A. Barlier G. Gunz A.J. Zamora I. Morange-Ramos D. Figarella-Branger H. Dufour A. Enjalbert P. Jaquet Prognostic and therapeutic consequences of Gsα mutations in somatotroph adenomas J. Clin. Endocrinol. Metab. 83 1998 1604 1610
7. A. Barlier I. Pellegrini-Bouiller G. Gunz A.J. Zamora F. Jaquet A. Enjalbert Impact of gsp oncogene on the expression of genes coding for Gsα, Pit-1, Gi2α, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity J. Clin. Endocrinol. Metab. 84 1999 2759 2765
8. A.S. Bates W.E. Farrell E.J. Bicknell A.M. McNicol A.J. Talbot J.C. Broome C.W. Perrett R.V. Thakker R.N. Clayton Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker J. Clin. Endocrinol. Metab. 82 1997 818 824
9. J.S. Bevan S.L. Atkin A.B. Atkinson P.M. Bouloux F. Hanna P.E. Harris R.A. James M. McConnell G.A. Roberts M.F. Scanlon P.M. Stewart E. Teasdale H.E. Turner J.A. Wass J.M. Wardlaw Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size J. Clin. Endocrinol. Metab. 87 2002 4554 4563
10. H.N. Buch D. Raskauskiene A. Bahar E.J. Bicknell W.E. Farrell R.N. Clayton Prediction of recurrence of nonfunctioning pituitary tumours by loss of heterozygosity analysis Clin. Endocrinol. 61 2004 19 25
11. L. Buscail J.P. Esteve N. Saint-Laurent V. Bertrand T. Reisine A.M. O’Carroll G.I. Bell A.V. Schally N. Vaysse C. Susini Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by the somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms Proc. Natl. Acad. Sci. U.S.A. 92 1995 1580 1584
12. P. Caron S. Arlot C. Bauters P. Chanson J.M. Kuhn M. Pugeat R. Marechaud C. Teutsch E. Vidal P. Sassano Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas J. Clin. Endocrinol. Metab. 86 2001 2849 2853
13. M.G. Cattaneo D. Amoroso G. Gussoni A.M. Sanguini L.M. Vicentini A somatostatin analogue inhibits MAPkinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines FEBS Lett. 397 1996 164 168
14. N.W. Cheung S.C. Boyages Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block Endocrinology 136 1995 4174 4181
15. R.N. Clayton M. Pfeifer A.B. Atkinson P. Belchetz J.A. Wass E. Kyrodimou M. Vanderpump D. Simpson J. Bicknell W.E. Farrell Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins Clin. Cancer Res. 6 2000 3973 3982
16. S. Corbetta E. Ballare G. Mantovani A. Lania M. Losa A.M. Di Blasio A. Spada Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression Eur. J. Clin. Invest. 31 2001 208 214
17. P. Cordelier J.P. Esteve C. Bousquet N. Delesque A.M. O’Carroll A.V. Schally N. Vaysse C. Susini L. Buscail Characterization of the antiproliferative signal mediated by somatostatin receptor subtype 5 Proc. Natl. Acad. Sci. U.S.A. 94 1997 9343 9348
18. P. Dasgupta Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis Pharmacol. Ther. 2 2004 61 85
19. W.W. de Herder L.J. Hofland A.J. van der Lely S.W. Lamberts Somatostatin receptors in gastroentero pancreatic neuroendocrine tumours Endocr. Relat. Cancer 10 2003 451 458
20. E. Ferrante C. Pellegrini S. Bondioni E. Peverelli M. Locatelli P. Gelmini P. Lucani A. Peri G. Mantovani S. Bosari P. Beck-Peccoz A. Spada A. Lania Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2 Endocr. Relat. Cancer 13 2006 955 962
21. M. Filopanti E. Ballare A.G. Lania S. Bondioni U. Verga M. Locatelli L.M. Zavanone M. Losa S. Gelmini A. Peri C. Orlando P. Beck-Peccoz A. Spada Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas J. Endocrinol. Invest. 27 2004 937 942
22. M. Filopanti C. Ronchi E. Ballare S. Bondioni A.G. Lania M. Losa S. Gelmini A. Peri C. Orlando P. Beck-Peccoz A. Spada Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly J. Clin. Endocrinol. Metab. 90 2005 4824 4828
23. T. Florio A. Scorziello M. Fattore V. D’Alto S. Salzano G. Rossi M.T. Berlingieri A. Fusco G. Schettini Somatostatin inhibits PC C13 thyroid cell differentiation through the modulation of phosphotyrosine activity J. Biol. Chem. 271 1996 6129 6136
24. T. Florio M. Morini V. Villa S. Arena A. Corsaro S. Thellung M.D. Culler U. Pfeffer D.M. Noonan G. Schettini A. Albini Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities Endocrinology 144 2003 1574 1584
25. P.U. Freda L. Katznelson A.J. van der Lely C.M. Reyes S. Zhao D. Rabinowitz Long-acting somatostatin analog therapy of acromegaly: a meta-analysis J. Clin. Endocrinol. Metab. 90 2005 4465 4473
26. N. Garcia de la Torre J.A. Wass H.E. Turner Antiangiogenic effects of somatostatin analogues Clin. Endocrinol. 57 2002 425 441
27. Y. Greenman S. Melmed Expression of three somatostatin receptor subtypes in pituitary adenomas:evidence for preferential SSTR5 expression in the mammosomatotroph lineage J. Clin. Endocrinol. Metab. 79 1994 724 729
28. S. Honda C. Tanaka-Kosugi S. Yamada T. Sano T. Matsumoto M. Itakura K. Yoshimoto Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene Endocr. J. 50 2003 309 318
29. L.J. Hofland S.W. Lamberts Somatostatin receptors in pituitary function, diagnosis and therapy Front. Horm. Res. 32 2004 235 252
30. L.J. Hofland S.W. Lamberts Somatostatin receptor subtype expression in human tumors Ann. Oncol. Suppl. 2 2001 S31 S36
31. L.J. Hofland S.W. Lamberts The patophysiological consequences of somatostatin receptor internalization and resistance Endocr. Rev. 24 2003 28 47
32. E. Hubina A.M. Nanzer M.R. Hanson E. Ciccarelli M. Losa D. Gaia M. Papotti M.R. Terreni S. Khalaf S. Jordan S. Czirjak Z. Hanzely G.M. Nagy M.I. Goth A.B. Grossman M. Korbonits Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours Eur. J. Endocrinol. 155 2006 371 379
33. N. Hukovic R. Panetta U. Kumar M. Rocheville Y.C. Patel The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization J. Biol. Chem. 273 1998 21416 21422
34. J. Iglese W.J. Koch K. Touhara R.J. Lefkowitz βγ interactions with PH domains and ras-MAPK signalling pathways Trends Biochem. Sci. 20 1995 151 156
35. P. Jaquet A. Saveanu G. Gunz F. Fina A.J. Zamora M. Grino M.D. Culler J.P. Moreau A. Enjalbert L.H. Ouafik Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes J. Clin. Endocrinol. Metab. 85 2000 781 792
36. R.A. James V.D. Sarapura C. Bruns F. Raulf J.M. Dowding D.F. Gordon W.M. Wood E.C. Ridgway Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor Endocrinology 138 1997 719 724
37. S.W.J. Lamberts E.P. Krenning J.C. Reubi The role of somatostatin and its analogs in the diagnosis and treatment of tumors Endocr. Rev. 12 1991 450 482
38. S.W. Lamberts W.W. de Herder L.J. Hofland Somatostatin analogs in the diagnosis and treatment of cancer Trends Endocrinol. Metab. 13 2002 451 457
39. C.A. Landis S.B. Masters A. Spada A.M. Pace H.M. Bourne L. Vallar GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours Nature 340 1989 692 696
40. P. Luciani S. Gelmini E. Ferrante A. Lania S. Benvenuti S. Baglioni G. Mantovani I. Cellai F. Ammannati A. Spada M. Serio A. Peri Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas J. Clin. Endocrinol. Metab. 90 2005 6156 6161
41. D.K. Ludecke T. Abe Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1000 operations Neuroendocrinology 83 3–4 2006 230 239
42. S. Melmed I. Jackson D. Kleimberg A. Klibanski Current treatment guidelines for acromegaly J. Clin. Endocrinol. Metab. 83 1998 2646 2652
43. S. Melmed R. Sternberg D. Cook A. Klibanski P. Chanson V. Bonert M.L. Vance D. Rhew D. Kleinberg A. Barkan A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly J. Clin. Endocrinol. Metab. 90 2005 4405 4410
44. S. Melmed Medical progress: acromegaly N. Engl. J. Med. 355 2006 2558 2573
45. M. Nyegaard A.D. Borglum T.G. Bruun D.A. Collier C. Russ O. Mors H. Ewald T.A. Kruse Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder Mol. Psychiatry 7 2002 745 754
46. K. Oberg Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment Curr. Opin. Oncol. 14 2002 38 45
47. D. O’Toole A. Saveanu A. Couvelard G. Gunz A. Enjalbert P. Jaquet P. Ruszniewski A. Barlier The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur. J. Endocrinol. 155 2006 849 857
48. C. Park I. Yang J. Woo S. Kim J. Kim Y. Kim S. Sohn E. Kim M. Lee H. Park J. Jung S. Park Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srifactivity and response to octreotide Endocr. J. 51 2004 227 236
49. J. Parma L. Duprez J. Van Sande P. Cochaux C. Gervy J. Mockel J. Dumont G. Vassart Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas Nature 365 1993 649 651
50. Y.C. Patel Molecular pharmacology of somatostatin receptor subtypes J. Endocrinol. Invest. 20 1997 348 367
51. Y.C. Patel C.B. Srikant Somatostatin receptor Trends Endocrinol. Metab. 10 1997 397 405
52. L. Pei S. Melmed B. Scheithauer K. Kovacs W.E. Benedict D. Prager Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors. Evidence for a chromosome 13 tumor suppressor gene other than RB Cancer Res. 55 1995 644 646
53. S. Petersenn M. Heyens D.K. Lüdecke F.U. Beil H.M. Schulte Absence of somatostatin receptor type 2A mutations and gip oncogene in pituitary somatotroph adenomas Clin. Endocrinol. (Oxf.) 52 2000 35 42
54. T. Reisine G.I. Bell Molecular biology of somatostatin receptors Endocr. Rev. 16 1995 427 442
55. S.G. Ren J. Taylor J. Dong R. Yu M.D. Culler S. Melmed Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion J. Clin. Endocrinol. Metab. 88 2003 4239 4245
56. J.C. Reubi A.M. Landolt The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status J. Clin. Endocrinol. Metab. 68 1989 844 850
57. J.C. Reubi B. Waser J.C. Schaer J.A. Laissue Somatostatin receptor SST1-SST5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur. J. Nucl. Med. 28 2001 836 846
58. M. Rocheville D.C. Lange U. Kumar R. Sasi R.C. Patel Y.C. Patel Subypes of somatostatin receptor assemble as functional homo- and heterodimers J. Biol. Chem. 275 2000 7862 7869
59. M. Rocheville D.C. Lange U. Kumar S.C. Patel R.C. Patel Y.C. Patel Receptor for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity Science 288 2000 154 157
60. A. Saveanu G. Gunz H. Dufour P. Caron F. Fina L. Ouafik M.D. Culler J.P. Moreau A. Enjalbert P. Jaquet Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J. Clin. Endocrinol. Metab. 86 2001 140 145
61. K. Sharma Y.C. Patel C.B. Srikant C-terminal region of the human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest Mol. Endocrinol. 13 1999 82 92
62. I. Shimon X. Yan J.E. Taylor M.H. Weiss M.D. Culler S. Melmed Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas J. Clin. Invest. 100 1997 2386 2392
63. D.J. Simpson J. Magnay J.E. Bicknell A.L. Barkan A.M. McNicol R.N. Clayton W.E. Farrell Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) despite loss of RB1 product in somatotropinomas Cancer Res. 59 1999 1562 1566
64. D.J. Simpson E.J. Bicknell H.N. Buch S.J. Cutty R.N. Clayton W.E. Farrell Genome-wide amplification and allelotyping of sporadic pituitary adenomas identify novel regions of genetic loss Genes Chromosomes Cancer 37 2003 225 236
65. A. Spada M. Arosio D. Bochicchio N. Buzzoni L. Vallar M. Bassetti G. Faglia Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumours with or without constitutively active adenylyl cyclase J. Clin. Endocrinol. Metab. 71 1990 1421 1426
66. P.M. Stewart Current therapy for acromegaly Trends Endocrinol. Metab. 11 2000 128 132
67. G.F. Taboada R.M. Luque W. Bastos R.F. Guimaraes J.B. Marcondes L.M. Chimelli R. Fontes P.J. Mata P.N. Filho D.P. Carvalho R.D. Kineman M.R. Gadelha Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas Eur. J. Endocrinol. 156 2007 65 74
68. J. Torrisani M. Bouisson E. Puente G. Capella P. Laurent-Puig A. Berger N. Vaysse C. Susini L. Buscail Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism Gastroenterology 120 2001 200 209
69. T. van Biesen L.M. Luttrell B.E. Hawes R.J. Lefkowitz Mitogenic signaling via G protein coupled receptors Endocr. Rev. 17 1996 698 714